| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| Other Sizes |
| Targets |
Not applicable. D-Xylofuranose, 1,2,3,5-tetraacetate is a synthetic intermediate with no biological target. It is a protected sugar used to introduce xylofuranose moieties into larger molecules. It has no direct pharmacological activity. The compound is used in the synthesis of nucleoside analogs, glycosyl donors, and other carbohydrate-based therapeutics.
|
|---|---|
| ln Vitro |
As a chemical intermediate, D-Xylofuranose, 1,2,3,5-tetraacetate has no direct in vitro biological activity. It is not tested in cell-based assays. Its value lies in its use as a building block for the synthesis of biologically active compounds, such as antiviral or anticancer nucleosides. The purity is typically ≥95-98%.
|
| ln Vivo |
No in vivo activity has been reported. As a synthetic intermediate, it is not administered to animals. The final products synthesized from this intermediate may have in vivo activity, but the intermediate itself is not used for in vivo studies.
|
| Enzyme Assay |
Not applicable. As a chemical intermediate with no biological target, no cell-free binding assays are performed. The compound is used in chemical reactions. Its identity and purity are confirmed by NMR, HPLC, and mass spectrometry. For use as a glycosyl donor, a typical chemical activation protocol involves dissolving D-Xylofuranose, 1,2,3,5-tetraacetate in anhydrous dichloromethane (DCM) and activating with a Lewis acid (e.g., BF3·OEt2, SnCl4, or TMSOTf) to generate an oxocarbenium ion intermediate, which can then react with an acceptor (e.g., an alcohol or a nucleobase) to form a glycosidic bond. The acetyl groups serve as protecting groups and can be removed under basic conditions (e.g., sodium methoxide in methanol) to yield free hydroxyls.
|
| Cell Assay |
Not applicable. The compound is not used for cell-based assays. It is a chemical intermediate stored as a solid at room temperature or under refrigeration. For use in chemical synthesis, it is typically dissolved in anhydrous DMF, DCM, or acetonitrile. Standard chemical safety precautions (gloves, goggles, fume hood) should be used when handling.
|
| Animal Protocol |
No in vivo animal studies are conducted with this compound. It is a chemical intermediate for organic synthesis, not a test article. Animal studies would be conducted with the final pharmaceutical product.
|
| ADME/Pharmacokinetics |
Not applicable. The compound is a chemical intermediate with no pharmacological use. It has no absorption, distribution, metabolism, or excretion properties of interest.
|
| Toxicity/Toxicokinetics |
No toxicity data is reported. D-Xylose is a naturally occurring sugar that is generally recognized as safe (GRAS). The acetylated derivative is a chemical intermediate, and standard chemical safety precautions should be used. The compound is not intended for human consumption.
|
| References | |
| Additional Infomation |
D-Xylofuranose, 1,2,3,5-tetraacetate is also known as 1,2,3,5-tetra-O-acetyl-alpha-D-xylofuranose. The molecular formula is C13H18O9, and the molecular weight is 318.28. The CAS number is 42927-46-8. The compound is a white to off-white crystalline solid. It is soluble in organic solvents such as chloroform, DCM, and DMSO. The compound is stored at 2-8degC and is protected from moisture. It is not approved for clinical use; it is a specialty chemical for research and development purposes only.
|
| Molecular Formula |
C13H18O9
|
|---|---|
| Molecular Weight |
318.28
|
| Exact Mass |
318.095
|
| CAS # |
42927-46-8
|
| PubChem CID |
11162923
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
0.7
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
22
|
| Complexity |
458
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC(OC[C@H]1OC(OC(=O)C)[C@H](OC(=O)C)[C@H]1OC(=O)C)=O
|
| InChi Key |
IHNHAHWGVLXCCI-DAAZQVBGSA-N
|
| InChi Code |
InChI=1S/C13H18O9/c1-6(14)18-5-10-11(19-7(2)15)12(20-8(3)16)13(22-10)21-9(4)17/h10-13H,5H2,1-4H3/t10-,11+,12-,13?/m1/s1
|
| Chemical Name |
[(2R,3S,4R)-3,4,5-triacetyloxyoxolan-2-yl]methyl acetate
|
| Synonyms |
D-Xylofuranose, 1,2,3,5-tetraacetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1419 mL | 15.7094 mL | 31.4189 mL | |
| 5 mM | 0.6284 mL | 3.1419 mL | 6.2838 mL | |
| 10 mM | 0.3142 mL | 1.5709 mL | 3.1419 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
